Overview

PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Status:
Recruiting

Trial end date:
2023-08-01

Target enrollment:

Participant gender:

Summary

A randomized controlled, multi-center, open, phase II clinical study is designed to target patients with resectable intrahepatic cholangiocarcinoma with high-risk recurrence factors which has extremely low postoperative recurrence-free survival. In this study, we aim to compare the prognosis in intrahepatic cholangiocarcinoma between Toripalimab combined with Lenvatinib and GEMOX neoadjuvant treatment and the current clinical surgical treatment (traditional group).

Phase:

Phase 2

Details

Lead Sponsor:

Shanghai Zhongshan Hospital

Collaborators:

Minhang Hospital, Fudan University
Shanghai Jinshan Hospital
Shenzhen University General Hospital
Xuhui Central Hospital, Shanghai